S 1131

Fair Accountability and Innovative Research Drug Pricing Act of 2017

Congress: 115 (2017–2019, Ended)
Chamber: Senate
Policy Area: Health
Introduced: May 16, 2017
Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (May 16, 2017)
Official Text: https://www.congress.gov/bill/115th-congress/senate-bill/1131

Sponsor

Name: Sen. Baldwin, Tammy [D-WI]
Party: Democratic • **State:** WI • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. McCain, John [R-AZ]	R · AZ		May 16, 2017

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	May 16, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 HR 2439	Related bill	**May 19, 2017:** Referred to the Subcommittee on Health.

Summary (as of May 16, 2017)

Fair Accountability and Innovative Research Drug Pricing Act of 2017

This bill amends the Public Health Service Act to require manufacturers of certain drugs and biological products with a wholesale cost of $100 or more per month to report to the Department of Health and Human Services (HHS) price increases that result in a 10% or more increase in the cost of a drug over a 12-month period or a 25% or more increase over a 36-month period. Reports are required for prescription drugs and drugs commonly administered in hospitals, except vaccines, drugs for rare conditions, and drugs with annual sales for Medicare and Medicaid enrollees of less than $1. Reports must contain specified information including pricing history and a justification for each price increase in the relevant period.

Manufacturers that do not submit a required report are subject to a civil penalty. Collected penalty funds must be used to carry out activities related to this reporting requirement and to improve consumer and provider information about drug value and drug price transparency.
HHS must publish manufacturer reports, a summary of those reports, and supporting analyses.

Actions Timeline

- **May 16, 2017:** Introduced in Senate
- **May 16, 2017:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.